에서 실시간으로 운영 중이에요! 자세히 알아보기
ADMA 아이콘

ADMA Biologics
ADMA

10.68 USD
-0.05
0.47%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
10.68
0.00
0%
1일
-0.47%
5일
3.49%
1개월
20%
3개월
21.23%
6개월
-0.56%
연초 이후
-40.27%
1년
-26.65%
5년
870.91%
10년
68.72%
 

소개: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

직원 수: 647

건강관리 생명공학

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 2.6%
중립 95.4%
부정적 2.1%
중립
GlobeNewsWire
어제
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
긍정적
Zacks Investment Research
4일 전
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
중립
Zacks Investment Research
8일 전
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
긍정적
Zacks Investment Research
8일 전
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
부정적
Zacks Investment Research
17일 전
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
중립
Zacks Investment Research
22일 전
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
긍정적
Zacks Investment Research
22일 전
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
긍정적
Zacks Investment Research
28일 전
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
중립
Newsfile Corp
지난달
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
부정적
Zacks Investment Research
지난달
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
뉴스 순위 보기
Lightweight Charts™를 사용해 가격 차트를 구현했어요.